The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
Integrating Type 2 symptoms into SLE management strategies
Betty Diamond
Murray Urowitz
Laurent ArnaudDuring the Lupus Hub Steering Committee Meeting, held on May 7, 2024, Murray Urowitz chaired a discussion on integrating Type 2 symptoms into management strategies for systemic lupus erythematosus (SLE), with contributions from Betty Diamond, and Laurent Arnaud.
Integrating Type 2 symptoms into SLE management strategies
Urowitz provided an overview of the key differences between the two types of lupus, highlighting the key symptoms of Type 2 lupus and their similarity to other conditions, such as COVID-19. He emphasized the importance of including these symptoms as outcome measures in clinical trials, and addressed patient–physician discordance and the need for a multidisciplinary approach involving social workers, nurses, psychologists, and psychiatrists. Although the pathogenesis of Type 2 lupus remains unclear, the steering committee members questioned the inflammatory contribution and the necessity of further investigation into its underlying mechanisms.
